Treatment of pediatric Takayasu arteritis with infliximab and cyclophosphamide: Experience from an American-Brazilian cohort study

Journal of Clinical Rheumatology

Volumn 20, Issue 4, 2014, Pages 183-188

  Stern, Sara ^a,d   Clemente, Gleice ^b   Reiff, Andreas ^c   Ramos, Margarida Paula Romão ^b   Marzan, Katherine Anne ^c   Terreri, Maria Teresa ^b  

^a UNIVERSITY OF UTAH   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

and infliximab; cyclophosphamide; pediatric vasculitis; Takayasu arteritis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AORTA ARCH SYNDROME; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FAINTNESS; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; NATIONAL HEALTH ORGANIZATION; OPPORTUNISTIC INFECTION; PARESTHESIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SINUSITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; BRAZIL; CHILD; DRUG COMBINATION; REMISSION; TAKAYASU ARTERITIS; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BRAZIL; CHILD; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLIXIMAB; MALE; REMISSION INDUCTION; TAKAYASU ARTERITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84901784015     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000106     Document Type: Article

References (49)

1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-929. (Pubitemid 24179154)
2. Nunes G, Neves FS, Melo FM, et al. Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol. 2010;50:291-298.
3. Brunner J, Feldman BM, Tyrrell PN, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49:1806-1814.
4. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72-76. (Pubitemid 44940894)
5. Buonuomo PS, Bracaglia C, Campana A, et al. Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol Int. 2011;31:93-95.
6. Filocamo G, Buoncompagni A, Viola S, et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr. 2008;153:432-434.
7. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296-2304. (Pubitemid 38924409)
8. Molloy ES, Langford CA, Clark TM, et al. Anti-tumor necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67:1567-1569.
9. Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-> in refractory Takayasu's arteritis: cases series and review of literature. Autoimmun Rev. 2012;11:678-684.
10. Zaharenia TK, Mavragani P, Papahanasiou MA, et al. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol. 2007;26:984-987.
11. Tripathy NK, Grupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol. 2006;118:154-158. (Pubitemid 43199653)
12. Arnaud L, Haroche J, Mathian A, et al. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev. 2011;11:61-67.
13. Morales E, Pineda C, Martinez-Lavin M. Takayasu arteritis in children. J Rheumatol. 1991;18:1081-1084.
14. Della Rossa A, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford). 2005;44:1074-1075. (Pubitemid 41487190)
15. Nascif AK, Lemos MD, Oliveira NS, et al. Takayasu's arteritis in children and adolescents: report of three cases. Rev Bras Reumatol. 2011;51:527-530.
16. Zhu WH, Shen LG, Neubauer H. Clinical characteristics, interdisciplinary treatment and follow-up of 14 children with Takayasu arteritis. World J Pediatr. 2010;6:342-347.
17. Jain S, Sharma N, Singh S, et al. Takayasu arteritis in children and young Indians. Int J Cardiol. 2000;75:S153-S157.
18. Jain S, Kumari S, Ganguly NK, et al. Current status of Takayasu arteritis in India. Int J Cardiol. 1996;54:S111-S116.
19. Dabague J, Reyes PA. Takayasu arteritis in Mexico: a 38 year clinical perspective through literature review. Int J Cardiol. 1996;54:S103-S109.
20. Hahn D, Thomson PD, Kala U, et al. A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr Nephrol. 1998;12:668-675. (Pubitemid 28472926)
21. Kaneko U, Kishi T, Kikuchi M, et al. Infliximab therapy for three adolescent patients with refractory Takayasu's arteritis. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33:317-323.
22. El-Matary W, Persad R. Takayasu's aortitis and infliximab. J Pediatr. 2009;155:151.
23. Schafer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol. 2012;24:31-37.
24. Quartuccio L, Schiavon F, Zuliani F, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol. 2012;30:922-928.
25. Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term follow up. Arthritis Care Res (Hoboken). 2012;64:1079-1083.
26. Mekinian A, Néel A, Sibilia J, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51:882-886.
27. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151-156.
28. Goel R, Danda D, Mathew J, et al. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol. 2010;29:329-332.
29. Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71:75-79.
30. Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol. 2012;2012:406963.
31. Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913-919. (Pubitemid 351747137)
32. Arend WP, Michel BA, Blotch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129-1134. (Pubitemid 20273298)
33. Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterization. Ann Rheum Dis. 2010;69:790-797.
34. Ozen S, Pistorio A, Lusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798-806.
35. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitis: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192. (Pubitemid 24065492)
36. Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996;54:S155-S163.
37. Moriwaki R, Noda M, Yajima M, et al. Clinical manifestations of Takayasu's arteritis in India and Japan: new classification of angiographic findings. Angiology. 1997;16:92-94.
38. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56:1000-1009. (Pubitemid 46399449)
39. Arnaud L, Haroche J, Limal N, et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore). 2010;89:1-17.
40. Shekhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu's arteritis and its therapy. Ann Intern Med. 1985;103:121-126. (Pubitemid 15068510)
41. Gardner JD, Lee KR, Abdou NI. Takayasu's arteritis: reversal of pulse deficit after early treatment with corticosteroids. J Rheumatol. 1984;1:92-93. (Pubitemid 14172152)
42. Sato EI, Lima N, Espirito Santo B, et al. Takayasu arteritis. Treatment and prognosis in a university center in Brazil. Int J Cardiol. 2000;75:S163-S166.
43. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu's arteritis. Ann Intern Med. 2011;155:425-433.
44. Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730-736. (Pubitemid 36612957)
45. 18F-FDG PET coregistered with enhanced CT. J Nucl Med. 2005;46:917-922. (Pubitemid 43733504)
46. Meller J, Grabbe E, Becker W, et al. Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol. 2003;13:400-405. (Pubitemid 36798619)
47. 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004;31:627-634. (Pubitemid 38647900)
48. Gornik HL, Creager MA. Aortitis. Circulation. 2008;117:3039-3051.
49. Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol. 2011;29:S43-S48.